Tag archive for ‘cancer’
ImmVira wraps up first dosing for MVR-T3011 in phase 2 trials in US and China
By businessnewstoday On Sunday, June 13th, 2021
0 Comments

ImmVira wraps up first dosing for MVR-T3011 in US and China

(adsbygoogle = window.adsbygoogle || []).push({}); ImmVira said that it has wrapped up the first dosing of its oncolytic virus product – MVR-T3011 intratumoral injection in phase 2 More...

Roche launches Elecsys Anti-p53 immunoassay to help in cancer diagnosis
By businessnewstoday On Sunday, April 11th, 2021
0 Comments

Roche launches Elecsys Anti-p53 immunoassay to help in cancer diagnosis

Swiss healthcare company Roche has launched the Elecsys Anti-p53 immunoassay to help in the diagnosis of various types of cancer by the in vitro quantitative determination of anti-p53 antibodies. The Anti-p53 immunoassay More...

Pyxis Oncology raises $152m in Series B round for cancer therapies
By businessnewstoday On Tuesday, March 30th, 2021
0 Comments

Pyxis Oncology raises $152m in Series B round for cancer therapies

Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by Arix Bioscience and RTW Investments. The company is developing antibody-drug conjugates (ADCs), immunotherapies, More...

Alkem Laboratories, Tata Memorial Centre to set up radiotherapy facility in Muzaffarpur
By businessnewstoday On Wednesday, March 24th, 2021
0 Comments

Alkem Laboratories, TMC to set up radiotherapy facility in Muzaffarpur

Alkem Laboratories and Tata Memorial Centre (TMC) have joined to set up an advanced radiotherapy facility in Muzaffarpur, Bihar as a part of the Homi Bhabha Cancer Hospital and Research Center (HBCHRC). As part More...

Day One Biopharmaceuticals, Merck sign licensing deal for MEK Inhibitors
By businessnewstoday On Tuesday, February 23rd, 2021
0 Comments

Day One Biopharmaceuticals, Merck sign licensing deal for MEK Inhibitors

Day One Biopharmaceuticals has signed a licensing agreement with Merck to develop and commercialize pimasertib and MSC2015103B, two oral, small molecule allosteric inhibitors of MEK 1/2. MEK 1/2 is a key enzyme More...

MSCP wraps up $330m sale of majority stake in Hojeij Branded Foods to Lagardere
By pharmanewsdaily On Sunday, January 10th, 2021
0 Comments

OncoSec Medical begins phase 2 OMS-104 melanoma trial with TAVO, OPDIVO combo

OncoSec Medical has dosed the first patient in the OMS-104 phase 2 clinical trial, which is evaluating TAVO (tavokinogene telseplasmid) in combination with OPDIVO (nivolumab) as a neoadjuvant therapy for melanoma. TAVO More...

By pharmanewsdaily On Sunday, December 6th, 2020
0 Comments

Olympus to acquire US medical device firm Veran Medical Technologies for $340m

Olympus Corporation has signed a deal worth up to $340 million to acquire Veran Medical Technologies (VMT), a Missouri-based provider of advanced medical devices specializing in interventional pulmonology. The Japanese More...

By pharmanewsdaily On Thursday, October 1st, 2020
0 Comments

CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer

US pharma giant Pfizer has entered into a collaboration deal worth up to $480 million with Chinese biopharma company CStone Pharmaceuticals to address the oncological needs in China. CStone Pharmaceuticals is engaged More...

MSCP wraps up $330m sale of majority stake in Hojeij Branded Foods to Lagardere
By pharmanewsdaily On Saturday, September 26th, 2020
0 Comments

Galecto raises $64m to develop fibrosis and cancer treatments

Galecto, a Danish biotech company, has raised $64 million in an equity financing round, for developing novel treatments for fibrosis and cancer. Led by Soleus Capital and co-led by Eir Ventures, the funding round More...

By pharmanewsdaily On Monday, September 21st, 2020
0 Comments

Illumina to take full ownership of cancer screening company GRAIL in $8bn deal

Illumina acquisition of GRAIL : US sequencing company Illumina has agreed to fully acquire California-based cancer screening company GRAIL in a cash and stock deal worth $8 billion. It was Illumina which had established More...